Page 28 - CIBEREHD-2015-eng

Platforms
BIOBANK
Hospital Clinic de Barcelona
Biobank (Biobanc Clinic)
The CIBEREHD has set up a platform which collects, stores and distributes biological samples connected with digestive diseases, supported by the infrastruc- ture of the IDIBAPS Biobank. This work includes two types of collections: gastrointestinal and pancreatic oncology (OGP) and intestinal diseases (EII).
(COLONTEST Project). Antoni Castells, assign- ment of 1075 serums.
• Identification of new biomarkers for prevention of colorectal cancer. Antoni Castells, assignment of 762 serums and 1398 DNA.
INTESTINAL INFLAMMATORY DISEASES (EII).
GASTROINTESTINAL AND PANCREATIC ONCOL- OGY (OGP). The Biobank has samples of plasma, serum, DNA and lymphocytes of donors with the fol- lowing characteristics:
• Patient with colorectal cancer: 283 donors.
• Patient with intermediate risk of colorectal can- cer: 5720 donors.
• Patient or relative with high risk of colorectal can- cer (polyposic or non-polyposic syndrome): 671 donors.
• Patient or relative with moderate risk of colorectal cancer (familial colorectal cancer): 48 donors.
• Patient with pancreatic cancer: 6 donors.
• Patient with intraductal papillary mucinous tu- mour or mucinous cystic tumour; 16 donors
• Patient with chronic pancreatitis: 19 donors.
• Patient with gastric cancer: 1 donor.
The samples are deposited at the IDIBAPS Biobank. In 2015 1291 new donors were received exclusive- ly from the Hospital Clínico de Barcelona. 1023 of these donors are patients with intermediate risk of colorectal cancer (79.2% new donations) and 142 patients or relatives with a high risk of colorectal cancer (11% new donations).
In 2015 a total number of 5358 different aliquots were assigned. The projects involved are as follows:
• Serum miR-21 as blood tests for early colorec- tal neoplasia. Francesc Balaguer, assignment of 800 serums and 800 plasmas.
• Metabolomics-based detection of early stage cancers. Kristi Kruusma, assignment of 523 se- rums.
• Design and preparation of kits for diagnosing co- lon cancer in the blood based on multiplex plat- forms
The Biobank mainly has samples of DNA (in some cases also of plasma and lymphocytes) of donors with the following characteristics:
• Crohn’s disease: 1575 donors.
• Ulcerative colitis: 769 donors.
• Indeterminate colitis: 15 donors.
• Lymphocytic colitis: 34 donors.
• Collagenous colitis: 39 donors.
• Intestinal diseases to be determined: 672.
The samples are deposited at the IDIBAPS Biobank. In 2015, 217 new donors were received, 197 of which (90.8% of the new donations) are from health centres in Catalonia other than the Hospital Clínic de Barce- lona. Furthermore, 108 of the donors are patients with Crohn’s disease (49.8% new donations) and 89 patients with ulcerative colitis (41% new donations).
In 2015 a total number of 43 aliquots of DNA were assigned to the project entitled Microbial-specific humoral response and HLA typing of Crohn’s dis- ease. Azucena Salas.
La Fe Hospital Biobank in Valencia
(Collection of Steatotic Livers)
La Fe Biobank is an authorised and consolidated service in the Hospital and the Healthcare Research Institute. It was authorised in 2013 by Royal Decree 1716/2011, of 18th November, by means of which the basic requisites for operation of biobanks for purpos- es of biomedical research were established.
In 2015, La Fe Biobank received 3253 donations from the collections that it has running until now, specifi- cally 36 in the biobank system. More specifically, two livers from the “Steatotic Liver” collection not valid for transplanting were donated for use in biomedical research. At the present time the collection has 173 livers characterised and managed according to nor- mative and quality criteria.
28 I Annual report 2015 I CIBEREHD